KIT and neoplasm: As bevacizumab failed in this patient, we selected arotinib in the second line, which is a small molecule multi target anti-angiogenesis drug that inhibits VEGFR 1/2/3 (vascular endothelial growth factor receptor 1/2/3) and other major tyrosine kinase receptors (such as FGFR1-4, PDGFR α/β, C-Kit, and FLT3) to potently block tumor angiogenesis and suppress proliferation.